In vitro Evaluation of Dextran-5-aminosalicylic Acid Conjugate as a Polymeric Colon-specific Prodrug of 5-aminosalicylic Acid |
Jung, Yun-Jin
(Laboratory of Biomedicinal, College of Pharmacy, Pusan National University)
Jeon, Hyun-Chu (Laboratory of Biomedicinal, College of Pharmacy, Pusan National University) Choi, Dea-Kyu (Laboratory of Biomedicinal, College of Pharmacy, Pusan National University) Kim, Young-Mi (Medicinal Chemistry, College of Pharmacy, Pusan National University) |
1 | B. H. Novis, Z. Korzets, P. Chen and J. Bernheim, Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br. Med. J (Clin. Res. Ed.) 296, 1442 (1988) |
2 | H. Kim, H. Kong, B. Choi, Y. Yang, Y. Kim, M. J. Lim, L. Neckers and Y. Jung, Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease, Pharm. Res., 22(9), 1499-509 (2005) DOI |
3 | H. Bronsted, L. Hovgaard and L Simons, Dextran hydrogels for colon-specific drug delivery III. In vitro and in vivo degradation, S.T.P. Pharma. Sciences, 5, 60-64 (1995) |
4 | Y. Jung, J. S. Lee, H. H. Kim, Y. T. Kim and Y.M. Kim, Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5 aminosalicylic acid, Arch. Pharm. Res., 21, 179-186 (1998) DOI ScienceOn |
5 | J. S. Lee, Y.J. Jung, M. J. Doh and Y.M. Kim, Synthesis and Properties ofdextran-nalidixic acid as a colon-specific prodrug ofnalidixic acid, Drug Development and Industrial Pharmacy, 27(4), 327-332 (2001) |
6 | V. R. Sinha and R. Kurnria, Colonic drug delivery: prodrug approach, Pharm. Res., 18, 557-564 (2001) DOI ScienceOn |
7 | A. Rubinstein, D. Nakar and A. Sintov, Chondroitin sulfate: a potential biodegradable carrier for conlon-specific drug delivery, Int. J Pharm., 84, 141-150 (1992) DOI ScienceOn |
8 | M. K. Chourasia and S. K. Jain, Pharmaceutical approaches to colon targeted drug delivery systems, J. Pharm. Pharm. Sci., 6, 33-66 (2003) |
9 | A. Rubinstein, Microbially controlled drug delivery to the colon, Biopharm. & Drug Disposition, 11, 465-475 (1990) DOI ScienceOn |
10 | D. M. Andrew, Dextran prodrugs for colonic-specific drug delivery: In Oral Colon Specific Drug Delivery, D. R. Friend (Ed.), CRC press, Boca Raton, FL., pp. 213-231 (1992) |
11 | E. M. Ryde, Low-molecular-weight azo compounds: In Oral Colon Specific Drug Delivery, D. R. Friend (Ed.), CRC press, Boca Raton, FL., pp. 143-152 (1992) |
12 | M. Ashore, J. Fell, D. Astwood, H. Sharma and P. Woodhead, An evaluation of pectin as a carrier for drug targeting to the colon, J. Control. Rei., 26, 213-219 (1993) DOI ScienceOn |
13 | C. Larsen, and M. Johansen, Dextrans as carriers for drug compounds-realized and potential applications, Arch. Pharm. Chemi., 92, 809-830 (1985) |
14 | T. W. Sery and E. J. Hehre, Degradation of dextrans by enzymes of intestinal bacteria, J. of Bacteriology, 66, 373-380 (1955) |
15 | B. Crotty and D. P. Jewell, Drug therapy of ulcerative colitis, Br. J Clin. Pharmacol., 34, 189-198 (1992) DOI ScienceOn |
16 | S. Ardizzone and G. B. Porro, Inflammatory bowel disease: new insights into pathogenesis and treatment, J Intern. Med., 252, 475-496 (2002) DOI ScienceOn |
17 | R. Lofberg, Review article: medical treatment ofmild to moderately active Crohn's disease, Aliment. Pharmacal. Ther, 17 Suppl 2, 18-22 (2003) |